198 related articles for article (PubMed ID: 19952305)
1. Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.
Zaitsev S; Spitzer D; Murciano JC; Ding BS; Tliba S; Kowalska MA; Bdeir K; Kuo A; Stepanova V; Atkinson JP; Poncz M; Cines DB; Muzykantov VR
J Pharmacol Exp Ther; 2010 Mar; 332(3):1022-31. PubMed ID: 19952305
[TBL] [Abstract][Full Text] [Related]
2. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
Zaitsev S; Spitzer D; Murciano JC; Ding BS; Tliba S; Kowalska MA; Marcos-Contreras OA; Kuo A; Stepanova V; Atkinson JP; Poncz M; Cines DB; Muzykantov VR
Blood; 2010 Jun; 115(25):5241-8. PubMed ID: 20410503
[TBL] [Abstract][Full Text] [Related]
3. Biocompatible coupling of therapeutic fusion proteins to human erythrocytes.
Villa CH; Pan DC; Johnston IH; Greineder CF; Walsh LR; Hood ED; Cines DB; Poncz M; Siegel DL; Muzykantov VR
Blood Adv; 2018 Feb; 2(3):165-176. PubMed ID: 29365311
[TBL] [Abstract][Full Text] [Related]
4. Blood clearance and activity of erythrocyte-coupled fibrinolytics.
Ganguly K; Krasik T; Medinilla S; Bdeir K; Cines DB; Muzykantov VR; Murciano JC
J Pharmacol Exp Ther; 2005 Mar; 312(3):1106-13. PubMed ID: 15525799
[TBL] [Abstract][Full Text] [Related]
5. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets.
Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE
Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759
[TBL] [Abstract][Full Text] [Related]
6. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.
Zaitsev S; Danielyan K; Murciano JC; Ganguly K; Krasik T; Taylor RP; Pincus S; Jones S; Cines DB; Muzykantov VR
Blood; 2006 Sep; 108(6):1895-902. PubMed ID: 16735601
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
8. The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics.
Gersh KC; Zaitsev S; Muzykantov V; Cines DB; Weisel JW
J Thromb Haemost; 2010 May; 8(5):1066-74. PubMed ID: 20149071
[TBL] [Abstract][Full Text] [Related]
9. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.
Murciano JC; Higazi AA; Cines DB; Muzykantov VR
J Control Release; 2009 Nov; 139(3):190-6. PubMed ID: 19616049
[TBL] [Abstract][Full Text] [Related]
13. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
Ganguly K; Goel MS; Krasik T; Bdeir K; Diamond SL; Cines DB; Muzykantov VR; Murciano JC
J Pharmacol Exp Ther; 2006 Mar; 316(3):1130-6. PubMed ID: 16284278
[TBL] [Abstract][Full Text] [Related]
14. Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent.
Gersh KC; Zaitsev S; Cines DB; Muzykantov V; Weisel JW
Blood; 2011 May; 117(18):4964-7. PubMed ID: 21389322
[TBL] [Abstract][Full Text] [Related]
15. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
Ganguly K; Murciano JC; Westrick R; Leferovich J; Cines DB; Muzykantov VR
J Pharmacol Exp Ther; 2007 Apr; 321(1):158-64. PubMed ID: 17215448
[TBL] [Abstract][Full Text] [Related]
16. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
[TBL] [Abstract][Full Text] [Related]
17. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
[TBL] [Abstract][Full Text] [Related]
18. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
[TBL] [Abstract][Full Text] [Related]
19. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
[TBL] [Abstract][Full Text] [Related]
20. Platelet-targeted thromboprophylaxis with a human serum albumin fusion drug: Preventing thrombosis and reducing cardiac ischemia/reperfusion injurywithout bleeding complications.
Song Y; Bienvenu LA; Bongcaron V; Prijaya SA; Maluenda AC; Walsh APG; McFayden JD; Pietersz GA; Peter K; Wang X
Theranostics; 2024; 14(8):3267-3281. PubMed ID: 38855181
[No Abstract] [Full Text] [Related]
[Next] [New Search]
